Go to Article
Excerpt from www.biospace.com
Pictured: Sign at the European Patent Office’s headquarters in Germany/iStock, Christian Ader
The European Patent Office has handed Moderna a victory in its patent dispute with Pfizer and BioNTech regarding its COVID-19 vaccine, according to The Financial Times which first reported the development on Friday.
In an oral decision, the European patent authority maintained the validity of Moderna’s patent ‘949 which describes and protects specific alterations to mRNA molecules designed to lower its immunogenicity, bypass the immune system and boost its translation in the body—as well as the potential uses of the modified mRNA.